The aim of this study was to examine the in vitro -in vivo correlation (IVIVC) of two immediate release formulations of levofloxacin 250 mg film coated tablet. In vitro release data were obtained for each formulation by using the USP apparatus II, in 0.1N HCl of pH 2.0. Twelve healthy subjects were randomly chosen for in vivo study. Blood samples were collected over 24 hour period and analyzed by validated HPLC method with UV detection to establish a correlation between in vitro release and in vivo absorption. f 2 and f 1 were determined for the time intervals of 5, 10, 15, 20, 25, 30, 45 Mean dissolution times (MDT) for local and reference products were obtained at 7.69 and 9.55 minutes respectively. The values of mean absorption time (MAT) were obtained at 8.27 and 27.96 minutes for local and reference products respectively. For in vitro and in vivo correlation, level A type was also done for both products. In case of level A correlation, a non linear type of relation was established which is typical for immediate release formulations.
INTRODUCTION
The Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) released a guidance that set the information which should be provided to CDER to assure continuing product quality and performance characteristics of immediate-release oral solid dosage formulations for specific post-approval changes. 1 Immediate Release (SUPAC IR) that has the major intent to reduce the number of preapproval supplements required for manufacturing changes. According to SUPAC IR guidance, a manufacturer will frequently need to demonstrate that the dissolution profiles of the pre-change product and post-change product are "similar". In Bangladesh all local manufacturers produce generic products by changing manufacturing process(s) or equipment(s) compare to the innovators′ products after getting approval from Drug Administration. That's why supplements for Scale-Up and Post approval Changes (SUPAC) are required for those local and generic Levofloxacin{(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate}is a quinoline carboxylic acid derivative with a broad antibacterial activity and effective against a variety of pathogens such as members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and commonly isolated gram-positive organisms such as Staphylococcus aureus and Streptococcus pneumoniae. It has enhanced activity against grampositive organisms. [4] [5] [6] Levofloxacin is rapidly and almost completely absorbed after oral administration and showed excellent tissue penetration by absorbing two-thirds of those in plasma. 7, 8 Peak plasma concentrations are usually attained one to two hours after oral dosing. 9, 10 In Bangladesh a good number of the local manufacturers produce levofloxacin 250 mg tablet. That's why we have chosen levofloxacin as sample drug and compared in-vitro dissolution profiles to establish in vitro-in vivo correlation of a local and innovator's product of levofloxacin. Study design and clinical protocol. This was a single center, single dose, randomized study. All volunteers received 250 mg single film coated tablet of both products: Reference formulation (A) or Local formulation (B). Volunteers were randomly divided into two groups (Group-1 and 2) consisting of 6 volunteers in each group. Group-1 received treatment A followed by treatment B with a seven-day washout period. This sequence of treatment is denoted by AB. Group-2 received treatment B followed by treatment A after the same washout period. This sequence of treatment is denoted as BA. In the first period, Group-1 received treatment A and Group-2 received treatment B. In the second period Group-1 received treatment B and Group-2 received treatment A. This type of study design is known as crossover design in statistical literature. 11 Each volunteer received the treatment with 250 mL of water in the morning after overnight fasting. A standard lunch was provided after 4 hours of dosing. Volunteers were monitored constantly for the period of 24 hours by a medical doctor.
MATERIALS AND METHODS
Subjects. The mean age ± SD was 25.63 ± 1.41 (24 to 28) years for all volunteers. Their mean body weight and mean height were 69.50 ± 4.72 (60 to 75) kg and 1.74 ± 0.04 (1.68 to 1.80) m respectively, giving a mean body mass index (BMI) of 22.89 ± 1.50 (20.50 to 25.0) kg/m 2 . Subjects were selected after examining the medical history, physical check up, chest X-ray, ECG, serological screening for infectious disease, and urine analysis. Exclusion criteria included any history of a significant gastrointestinal condition that could potentially impair the absorption or disposition of the study medicine, previous history of allergy to any
fluoruquinolone, need for any chronic medication (e.g. theophylline, antacid, glibenclamide, phenytoin, iron or vitamins), donation of blood within 30 days preceding the first dose of the study or use of a investigational agent within 30 days of study entry. The volunteers were asked to abstain from taking any medication (including over-the-counter drugs) throughout the study; and from smoking, taking alcohol or caffeine or consuming xanthenecontaining beverages or food for at least 48 hours prior to, and throughout the study. Any incidence of vomiting or any other adverse events found in the volunteer(s) were excluded from the study. They were informed about the risks, benefits, procedures, and aims of the study, as well as their rights as research subjects. The study was conducted according to the Declaration of Helsinki (1964). Each volunteer signed an informed consent document and data collection form before entering the study. Ethical permission was taken to approve the protocol and consent form of this study from Ethical Review Committee of Bangladesh Medical Research Council (BMRC).
Blood sampling. The timing of blood collection was planned according to the previously reported value of time to reach peak serum concentration (T max ) and serum elimination half-life (t 1/2 ).
12-15 An intravenous cannula was placed into the volunteers' forearm vein before drug administration and left in place until the 24-hour blood sample was collected. Venous blood samples were collected before, and at 0.25, 0.50, 0.75, 1.00, 1.50, 2, 3, 5, 7, 9, 12 and 24 hours after drug administration. The blood samples were collected in coded, evacuated tubes, kept 30 minutes for clotting and centrifuged at room temperature (3000 rpm for 15 minutes). The serum was collected in coded eppendorf tubes and serum protein was separated by precipitation with ethanol followed by centrifugation at 10,000 rpm for 5 minutes. The serum was collected and stored at − 80°C until further analysis.
Data Analysis. The area under the plasma concentration-time curve to 24 hr (AUC 0-24 ) was determined by the trapezoidal rule, and the area under the serum concentration-time curve extrapolated to infinity (AUC 0-∞ ) was calculated according to the following formula:
AUC 0-∞ = AUC 0-t + C t /K el , where C t is the last quantifiable serum level. 16 The Similarity factor (f 2 ) and difference factor (f 1 ) were also determined by using the equation developed by Moor and Flanner (equations 2 and 3).
Where R t and T t are the percent drug dissolved at each time point for the reference and test products, respectively; n is the number of dissolution sample times and t is the time points for collecting dissolution samples.
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The Mean Dissolution Time (MDT in vitro ), Mean Absorption Time (MAT in vivo ) were also calculated both for local and reference formulations by using equations (4) and (5). 17, 18 MDT in vitro = t mid ∆M / ∆M ---------(Eq. 4)
Here, t mid is the time at mid point between i and i-1, ∆M is the additional amount of drug dissolved between i and i-1, ∆M in vivo is the additional amount of drug absorbed between i & i-1.
RESULTS AND DISCUSSION
The dissolution results for individual tablets are listed in Table 1 and presented graphically in the Figure 1 . From the graphical presentation it was observed that the dissolution pattern of Reference (Tavanic ® ) product was almost similar to that of Local (Trevox ® ) product. Similarity factors (f 2 ) and difference factors (f 1 ) for reference and local products are also presented in Table 1 . For both products the percent of drug released was calculated from dissolution profiles & percent of drug absorbed for both reference and local formulations were obtained from the equation 1 and have been shown in Table 2 . Similar type of curve was obtained from percent drug absorbed versus time plot for both products ( Figure  3) . The values of MDT in vitro and MAT in vivo were also presented in the table 3 both for local and reference formulation. 
In vitro -In vivo relationship
Determination of Level A correlation. Level A correlation is the highest category of correlation and represents a point-to-point (1:1) relationship between in vitro dissolution rate and in vivo input rate of the drug from the dosage form. 19 For level A correlation, percent of drug released from immediate release film coated tablet was determined, for both reference and local products, according to compendia dissolution method using Apparatus II (paddle apparatus) which has been discussed earlier and the results are presented in the Table 1 .
Percent of drug absorbed was calculated from the mean serum drug concentrations, using WagnerNelson equation (Equation-1) for both reference and local products (Table 2) . Then the values of percent of drug released were plotted against the percent of drug absorbed to find out the relationship (Figure 4 ). From the table 3, the mean absorption time (MAT) for local formulation is shorter due to low mean dissolution time (MDT) and opposite circumstance for reference formulation.
Percent of drug absorbed from local product and reference product have followed similar pattern and they are very close to each other in our study ( Figure  2 and 3 ). That's why initially we observed a gradual increase of the percent of drug absorbed both for local and reference product with a rapid increase in the terminal phase (Figure 4) . In level A correlation, we might conclude that there is no linear correlation between percent of drug release & percent of drug absorbed for both products.
Levofloxacin film coated tablet is an Immediate Release formulation. As dissolution is not a ratelimiting step in IR products, the fraction of drug Percent drug absorbed absorbed against the fraction of drug released profile would be non-linear type which was obtained in our present study. Since absorption cannot "keep up" with dissolution, a nonlinear relationship between the fractions of drug absorbed and the fractions of drug released was obtained. So it may be concluded that the In vitro -In vivo correlation is well established and justified for both local (test) and reference formulations by level A correlation.
